Literature DB >> 16715037

Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia.

Martin Witzenrath1, Birgitt Gutbier, Andreas C Hocke, Bernd Schmeck, Stefan Hippenstiel, Katharina Berger, Timothy J Mitchell, Juan R de los Toyos, Simone Rosseau, Norbert Suttorp, Hartwig Schütte.   

Abstract

OBJECTIVE: Acute respiratory failure is a significant complication of severe pneumococcal pneumonia. In a mouse model, we observed early-onset lung microvascular leakage after pulmonary infection with Streptococcus pneumoniae, and we hypothesized that the important virulence factor pneumolysin may be the direct causative agent.
DESIGN: Controlled, in vivo, ex vivo, and in vitro laboratory study.
SETTING: Laboratory.
SUBJECTS: Female mice, 8-12 wks old.
INTERVENTIONS: Ventilated and blood-free perfused murine lungs were challenged with recombinant pneumolysin via the airways as well as via the vascular bed. In addition, we analyzed the impact of pneumolysin on electrical cell impedance and hydraulic conductivity of human umbilical vein endothelial cell (HUVEC) and alveolar epithelial cell (A549) monolayers.
MEASUREMENTS AND MAIN RESULTS: Aerosolized pneumolysin dose-dependently increased capillary permeability with formation of severe lung edema but did not affect pulmonary vascular resistance. Intravascular pneumolysin caused an impressive dose-dependent increase in pulmonary vascular resistance and in lung microvascular permeability. By immunohistochemistry, pneumolysin was detected mainly in endothelial cells of pulmonary arterial vessels, which concomitantly displayed strong vasoconstriction. Moreover, pneumolysin increased permeability of HUVEC and A549 monolayers. Interestingly, immunofluorescence of endothelial cell monolayers exposed to pneumolysin showed gap formation and moderate stress fiber generation.
CONCLUSIONS: Pneumolysin may play a central role for early-onset acute lung injury due to severe pneumococcal pneumonia by causing impairment of pulmonary microvascular barrier function and severe pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715037     DOI: 10.1097/01.CCM.0000220496.48295.A9

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  60 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema.

Authors:  Rudolf Lucas; Supriya Sridhar; Ferenc G Rick; Boris Gorshkov; Nagavedi S Umapathy; Guang Yang; Aluya Oseghale; Alexander D Verin; Trinad Chakraborty; Michael A Matthay; Evgeny A Zemskov; Richard White; Norman L Block; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

3.  Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells.

Authors:  Sarah Statt; Jhen-Wei Ruan; Li-Yin Hung; Ching-Yun Chang; Chih-Ting Huang; Jae Hyang Lim; Jian-Dong Li; Reen Wu; Cheng-Yuan Kao
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

4.  Bioreactor for the long-term culture of lung tissue.

Authors:  Thomas H Petersen; Elizabeth A Calle; Maegen B Colehour; Laura E Niklason
Journal:  Cell Transplant       Date:  2010-11-19       Impact factor: 4.064

Review 5.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

6.  A novel tumor necrosis factor-mediated mechanism of direct epithelial sodium channel activation.

Authors:  István Czikora; Abdel Alli; Hui-Fang Bao; David Kaftan; Supriya Sridhar; Hans-Jürgen Apell; Boris Gorshkov; Richard White; Astrid Zimmermann; Albrecht Wendel; Meike Pauly-Evers; Jürg Hamacher; Irène Garcia-Gabay; Bernhard Fischer; Alexander Verin; Zsolt Bagi; Jean Francois Pittet; Waheed Shabbir; Rosa Lemmens-Gruber; Trinad Chakraborty; Ahmed Lazrak; Michael A Matthay; Douglas C Eaton; Rudolf Lucas
Journal:  Am J Respir Crit Care Med       Date:  2014-09-01       Impact factor: 21.405

7.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

8.  Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury.

Authors:  Danielle Salha; Jason Szeto; Lisa Myers; Carol Claus; Anthony Sheung; Mei Tang; Belma Ljutic; David Hanwell; Karen Ogilvie; Marin Ming; Benjamin Messham; Germie van den Dobbelsteen; Robert Hopfer; Martina M Ochs; Scott Gallichan
Journal:  Infect Immun       Date:  2012-04-02       Impact factor: 3.441

9.  Pneumolysin Mediates Platelet Activation In Vitro.

Authors:  Jan Gert Nel; Chrisna Durandt; Timothy J Mitchell; Charles Feldman; Ronald Anderson; Gregory R Tintinger
Journal:  Lung       Date:  2016-05-18       Impact factor: 2.584

10.  Role of Toll-like receptors 2 and 4 in pulmonary inflammation and injury induced by pneumolysin in mice.

Authors:  Mark C Dessing; Robert A Hirst; Alex F de Vos; Tom van der Poll
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.